German China

USA: Optimization of Analytical Workflow Research Collaboration Between Waters and BTI to Accelerate Biologics Production

Editor: Alexander Stark

Waters Corporation announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology and Research (A*Star). Among their new collaborative projects, the partners have started work on applying analytics that can help ensure overall safety, accuracy, and speed of biologics manufacturing.

Related Company

Waters expands its existing collaboration with the Bioprocessing Technology Institute, A*Star into new areas meant to accelerate bioprocessing and bioinformatics research.
Waters expands its existing collaboration with the Bioprocessing Technology Institute, A*Star into new areas meant to accelerate bioprocessing and bioinformatics research.
(Source: Public Domain / Pixabay )

Milford/USA; Singapore — In an extended collaboration with Singapor's Bioprocessing Technology Institute, Waters is exploring new areas meant to accelerate bioprocessing and bioinformatics research. Joint projects include developing analytical workflows for nucleic acid therapeutic products and bioinformatics research to deliver robust and accurate identification for a variety of biomolecules. The partners seek to improve the speed and accuracy of analytical workflows to help reduce costs, mitigate risks, and accelerate production of biologics.

Waters and BTI are engaging in data analytics research meant to eliminate a major bottleneck in the characterization of biopharmaceuticals, namely the identification and quantitation of complex biomolecules such as released N- and O- glycans and metabolites that influence therapeutic function. Isomerism of both glycans and metabolites is particularly troublesome and can be tackled using Waters’ instruments. However, because the data generated is massive, advanced bioinformatics approaches and machine learning techniques are needed to deliver robust and accurate identification for these and other biomolecules to overcome time-consuming and expensive conventional methods and current analytical software that cannot adequately interpret or visualize the data.

As part of the project, the US company will contribute scientific expertise and the use of their instruments including the Synapt series mass spectrometry system along with a Bio Accord LC-MS System. The SYNAPT instrument features ion mobility mass spectrometry technology to provide complete characterization of complex compounds and molecules. The Bio Accord system can be used to monitor product quality attributes in real time that can affect efficacy and safety of innovator drugs and biosimilars.

First established in 2014, Waters’ collaborative relationship with BTI has focused on evaluating the performance of a new N-linked glycan label aimed at biopharmaceutical applications, the Glyco Works Rapi Fluor-MS Glycan Kit, and its complete workflow – from sample preparation to analysis — for glycosylation profiling.

(ID:47493393)